ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,091.21
-1.02%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. TG Therapeutics Inc (TGTX) Quote

TG Therapeutics Inc

TG Therapeutics Inc (TGTX)

NASDAQ
13.47
-0.44
(-3.16%)
Closed April 26 4:00PM
Delayed by 15 minutes
13.57
0.10
(0.74%)
After Hours: 7:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
13.57
Bid
13.50
Ask
13.57
Volume
2,840,666
13.41 Day's Range 14.005
6.46 52 Week Range 35.67
Market Cap
2.082B
Previous Close
13.91
Open
13.94
Last Trade
10
@
13.47
Last Trade Time
Financial Volume
$ 38,702,969
VWAP
13.6246
Average Volume (3m)
3,455,938
Shares Outstanding
154,420,772
Dividend Yield
-
PE Ratio
164.19
Earnings Per Share (EPS)
0.08
Revenue
233.66M
Net Profit
12.67M

About TG Therapeutics Inc

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tgtherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
TG Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TGTX. The last closing price for TG Therapeutics was $13.91. Over the last year, TG Therapeutics shares have traded in a share price range of $ 6.46 to $ 35.67.

TG Therapeutics currently has 154,420,772 shares outstanding. The market capitalization of TG Therapeutics is $2.08 billion. TG Therapeutics has a price to earnings ratio (PE ratio) of 164.19.

TG Therapeutics (TGTX) Options Flow Summary

TGTX Options Flow

Overall Flow

Bearish

Net Premium

-252k

Calls / Puts

50.00%

Buys / Sells

66.67%

OTM / ITM

20.00%

Sweeps Ratio

0.00%

TGTX Latest News

More News

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating...

April 18 2024
GlobeNewswire Inc.

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for...

April 18 2024
GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating...

April 15 2024
GlobeNewswire Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3...

March 08 2024
GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b...

March 01 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

February 29 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET    NEW...

February 28 2024
GlobeNewswire Inc.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office...

February 27 2024
GlobeNewswire Inc.

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG Therapeutics) today announced that its ex-US partner, Neuraxpharm Group (Neuraxpharm), a leading European...

February 26 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-2.1629416005813.8714.56513.26314927613.98884748CS
4-1.56-10.310641110415.1315.3713.26270776414.27854369CS
12-2.93-17.757575757616.519.017512.84345593815.29431743CS
266.591.93776520517.0722.676.89498655614.5390951CS
52-8.76-39.229735781522.3335.676.46478192615.84945065CS
156-29.29-68.338777414842.8645.53.48346539914.62168756CS
2605.4867.73794808418.0956.743.48276968316.33860129CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

TGTX Discussion

View Posts
Monksdream Monksdream 4 months ago
TGTX new 52 week high
👍️0
InspectorBullit InspectorBullit 5 months ago
this should have a very good day tomorrow absent a market meltdown. MS drug par excellence.
👍️0
murocman murocman 6 months ago
I would think we’d be close to the bottom here? Almost at a 52 week low!

GLTA,

Murocman
👍️ 1
kld2 kld2 8 months ago
Cheap at these levels. Should see $20 again before long. Friday should be interesting. If script numbers are good, like last Friday, the share price should get a good boost. Half way through Q3. Dumb drop from $21 to $9.
👍️ 1
Max77 Max77 8 months ago
$TGTX CEO Weiss buys 100k shares at 10.13. Now has 12 million shares
👍️ 1
murocman murocman 9 months ago
Barely above pre-approval prices. Unbelievable.

Murocman
👍️ 1
teifhals teifhals 11 months ago
Anyone catch that Genetech is starting to air commercials since they are losing share?
👍️0
Rayn_Makr Rayn_Makr 12 months ago
Great call this morning. Nice run today and just the beginning with Europe coming on soon.
After Hours Time (ET) After Hours Price After Hours Share Volume
17:27:17 $30.5 5,000
$152,500 in one trade. Short covering???
Fun to think about market cap in 2024 and 2025.
👍️0
Alan Brown Alan Brown 1 year ago
Where did you find such news?
👍️0
Aquahoya Aquahoya 1 year ago
Has anyone checked out $GSTC? Similar biotech company like $TGTX except its much newer and has a patented formulation combinational therapy already FDA approved set and waiting for clinical trial approval in India for Multiple Sclerosis. It is an over-the-counter stock sitting over .01 just waiting for clinical trials approval. The market cap is on $8,000,000. The therapy isn't specific to the type of multiple sclerosis. So, the potential here is huge. The conservative market share that was done by seasoned professionals in the space, that is on their presentation is in the BILLIONs. Read the history here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170524593












👍️0
teifhals teifhals 1 year ago
Whens the buyout..?
👍️ 1
Penny chatter Penny chatter 1 year ago
Lol
👍️0
hawkshaw812 hawkshaw812 1 year ago
Looks like tuseday is shorting day .
👍️0
tw0122 tw0122 1 year ago
They have cash and a better MS drug have the price of Roches. Shorts don’t like
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Not only that but they must be...............

On the wrong side of the trade.

When you get squeezed on them nards, it never feels good.


No mercy....... TAKE THEM OUT !!!!!!!


GO $TGTX
👍️0
tw0122 tw0122 1 year ago
Analysts keep on giving it bad sell ratings.
That must be a good sign. Analysts for the most part just share selling scam artists
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Slowllyy creeping up..... now 11.50 in PreMarket

If it can do exactly what $KALA just did by going over $45, I'm a happy camper


GOOOOOOOOOOOooooooooooooooooooooooooooo hardddddddddddddddddddd



GO $TGTX
👍️0
Ringrock Ringrock 1 year ago
Traded@55.70 Jan 8 ‘21… looks like she’s still got quite a bit togo…
👍️0
shamalamadingdong shamalamadingdong 1 year ago
Dosing of first patients in 30 to 45 days from now/going to the market!!
👍️0
TheFinalCD TheFinalCD 1 year ago
$TGTX No offerings on the horizon per CC

$TGTX No offerings on the horizon per CC lfg— Cooway Trades 🐊 ⛪️🚀🇺🇸🙏🏽 (@cooway) December 29, 2022
👍️0
shamalamadingdong shamalamadingdong 1 year ago
Link to 8;30 webcast/conference call.
https://ir.tgtherapeutics.com/events
👍️0
shamalamadingdong shamalamadingdong 1 year ago
Some informative information, pictures of the packaging, disease overview, and more.
https://ml.globenewswire.com/1.0/snippet/1898/eng
👍️0
shamalamadingdong shamalamadingdong 1 year ago
TG Therapeutics Announces FDA Approval Of BRIUMVI; Company To Host Conference Call On Thursday, December 29, 2022 At 8:30 Am ET
👍️0
airman1 airman1 1 year ago
Given a try; on this one in at 8:47 for a morning was jump !!
See if shorts cover before the weekend ??
👍️0
airman1 airman1 1 year ago
Yeah, we may get mm naked! shorts covering tomorrow. Share price may
spike./;)) early GL$$
👍️0
tw0122 tw0122 1 year ago
They have cash and they would let the price go much higher before another offering
👍️0
tw0122 tw0122 1 year ago
$8.73 after hours On a good note company conference 830am and market makers
👍️0
pennyfinder pennyfinder 1 year ago
Probably an offering coming.
👍️0
tw0122 tw0122 1 year ago
Unfortunately lots of illegal naked shorts courtesy of Gary G but see what happens next few days as more shorts cover.
Never a easy game kept a few shares
👍️0
Cheap Stock Investor Cheap Stock Investor 1 year ago
Damn how low is this going? Not headed in right direction at the moment.
👍️0
tw0122 tw0122 1 year ago
MS drug going to make hundreds of millions..

Dec 28 (Reuters) - TG Therapeutics Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up nearly 9% in afternoon trade.

The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

TG Therapeutics said it was expecting to launch the drug, branded as Brumvi, in the first quarter of 2023, but did not give details on its pricing.

Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

Unlike other MS drugs that target T cells, Brumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to neurological disease.

The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients. (Reporting by Sriparna Roy, Khushi Mandowara and Raghav Mahobe in Bengaluru; Editing by Anil D'Silva and Shailesh Kuber)
👍️0
SpaceTimeRift777 SpaceTimeRift777 1 year ago
Nice Pump Moon Market
👍️0
tw0122 tw0122 1 year ago
As usual they going to scare folks into
Selling there shares loooks like upper $8s bottom
👍️0
tw0122 tw0122 1 year ago
Still holding about 20% regular short interest and then all the illegal naked Gary G approved ones
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Opens at $11...........


Only the beginning now


GO $TGTX
👍️0
tw0122 tw0122 1 year ago
Can be whatever you want if we see $40s..lol
👍️0
Imarket13 Imarket13 1 year ago
God damn thought you were a woman this whole time
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: I showered.............

Balls, armpits and buttcrack............. good to go.

Took 2mins


GO $TGTX
👍️0
tw0122 tw0122 1 year ago
220pm stand corrected
alfred

@macronewswire
TG THERAPEUTICS (TGTX)TO RESUME TRADING AT 2:20 P.M.
$TGTX
👍️0
Imarket13 Imarket13 1 year ago
I'm hearing within the next hour... everyone wins!!
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Fantastic !!!!!!!!!!!!!


Works for me



GO $TGTX
👍️0
tw0122 tw0122 1 year ago
Halted I believe until 830am
Press release tomorrow. Don’t take my word but pretty sure
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Whats the big deal about PKPH ???

Did they just get an FDA approval like $TGTX ??

GO $TGTX
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: No comment


I hope it doesn't open till tomorrow............. then yer filthy for the next 23hrs



GO $TGTX
👍️0
halbroke1 halbroke1 1 year ago
makin..TGTX nice one, Im In !!.Check out pk*ph.., Real cheap
👍️0
Imarket13 Imarket13 1 year ago
Well they should be. Clean trading is key
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Then go do whatever it is you do..........


TGTX doesn't care if you wanna shower.
Stocks arent concerned about your hygiene.


GO $TGTX
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: Remember when TGTX was $55 last year .................


And we didn't have anything like this FIRE news today.


Time to make up for some lost ground, and then some

We'd be at $1 now if it never got approved


GO $TGTX
👍️0
Imarket13 Imarket13 1 year ago
I have to take a shower
Want to see it open first
👍️0
makinezmoney makinezmoney 1 year ago
$TGTX: When it wants............



Whats the rush ???


GO $TGTX
👍️0

Your Recent History

NASDAQ
TGTX
TG Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved